Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Aptose Acquires China Rights to Leukemia Candidate in $125 Million Agreement

publication date: Jun 15, 2018

Aptose Biosciences of San Diego has added greater China to its in-licensing deal for a leukemia candidate discovered by Korea's CrystalGenomics. Aptose paid $3 million upfront and agreed to additional milestones along with a single-digit royalty on sales, totaling up to $125 million. CG-806 is a novel pre-clinical small molecule treatment for acute myeloid leukemia. In 2016, Aptose signed an $303 million option agreement for CG-806, excluding China and Korea. Last month, Aptose exercised that option ahead of schedule. More details....

Stock Symbols: (NSDQ: APTO; TSX: APS) (KOSDAQ: 083790)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.